ANAPTYSBIO, INC — Director's Dealing 2017

Jan 31, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAPTYSBIO INC (ANAB)
CIK: 0001370053
Period of Report: 2017-01-31

Reporting Person: Frazier Healthcare VII, L.P. (10% Owner)
Reporting Person: Frazier Healthcare VII-A, L.P. (10% Owner)
Reporting Person: FHM VII, L.P. (10% Owner)
Reporting Person: FHM VII, L.L.C. (10% Owner)
Reporting Person: FRAZIER ALAN D (10% Owner)
Reporting Person: Naini Nader J (10% Owner)
Reporting Person: Every Nathan R (10% Owner)
Reporting Person: Heron Patrick J (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-31	Common Stock	C	1428571	—	Acquired	1428571	Indirect
2017-01-31	Common Stock	C	604055	—	Acquired	604055	Indirect
2017-01-31	Common Stock	C	195751	—	Acquired	195751	Indirect
2017-01-31	Common Stock	C	733740	—	Acquired	733740	Direct
2017-01-31	Common Stock	C	209095	—	Acquired	209095	Indirect
2017-01-31	Common Stock	P	311291	$15.00	Acquired	311291	Direct
2017-01-31	Common Stock	P	88709	$15.00	Acquired	88709	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-31	Series B Preferred Stock	$	C	1428571	Disposed		Common Stock (1428571)	Indirect
2017-01-31	Series C Preferred Stock	$	C	604055	Disposed		Common Stock (604055)	Indirect
2017-01-31	Series C-1 Preferred Stock	$	C	195751	Disposed		Common Stock (195751)	Indirect
2017-01-31	Series D Preferred Stock	$	C	733740	Disposed		Common Stock (733740)	Direct
2017-01-31	Series D Preferred Stock	$	C	209095	Disposed		Common Stock (209095)	Indirect

Footnotes

F1: The Series B Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series B Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.

F2: The Series C Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.

F3: The Series C-1 Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series C-1 Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.

F4: The Series D Preferred Stock converted into Common Stock on a 1-to-1 basis immediately prior to the consummation of the Issuer's initial public offering without payment of considerations. The Series D Preferred stock were convertible automatically immediately prior to the consummation of the Issuer's initial public offering, and the shares had no expiration date.

F5: Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.

F6: Represents shares held by Frazier Healthcare VII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.

F7: Represents shares held by Frazier Healthcare VII-A, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.